JPH10502527A - TGF−βファミリーの新規な成長/分化因子 - Google Patents
TGF−βファミリーの新規な成長/分化因子Info
- Publication number
- JPH10502527A JPH10502527A JP8503546A JP50354696A JPH10502527A JP H10502527 A JPH10502527 A JP H10502527A JP 8503546 A JP8503546 A JP 8503546A JP 50354696 A JP50354696 A JP 50354696A JP H10502527 A JPH10502527 A JP H10502527A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sequence
- tgf
- cells
- family
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.TGF- βファミリーの一つのタンパク質をコードし、 (a)配列番号1のヌクレオチド配列の成熟タンパク質をコードする部分 及び任意の別の機能的な部分、 (b)遺伝コードの縮重の範囲内である(a)の配列に対応するヌクレオチド 配列、 (c)(a)又は(b)の配列のうちの1つの対立遺伝子誘導体に対応するヌク レオチド配列、または (d)起源が他の脊椎動物であることにより配列(a)とは異なる配列 (e)(a)、(b)、(c)または(d)の配列のうちの1つの配列とハイブリダイ ズするヌクレオチド配列 を含み、ただし、(d)によるDNA分子は少なくともTGF-βファミリーの成熟タ ンパク質をコードする部分を完全に含むDNA分子。 2.請求項1の(a)から(e)のうちの1つに加え、もう1種の別のタンパク質の少 なくとも一部をコードし、発現後に融合タンパク質が生成されるようにした核酸 配列を有する請求項1記載のDNA分子。 3.請求項1又は2に記載のDNA分子を少なくとも1コピーを含んでいるベク ター。 4.請求項1又は2に記載のDNA、又は請求項3に記載のベクターで形質転換 した宿主細胞。 5.細菌、真菌、植物又は動物細胞である請求項1に記載の宿主細胞。 6.請求項1又は2に記載のDNA配列によってコードされるTGF-βファミリー のタンパク質。 7.配列番号2又は配列番号4、又は所望によりそれらの機能的な部分のアミノ 酸配列を有する請求項6に記載のタンパク質。 8.請求項6又は7に記載のタンパク質と、もう1種の他のタンパク質の少なく とも一部分を含むキメラタンパク質。 9.請求項6、7、又は8のいずれかに記載のタンパク質のモノマー、及び「シ スチンノットモチーフ」(cystine knot motif)を有するスーパーファミリーの1 種のタンパク質のモノマーからなるヘテロダイマータンパク質。 10.請求項4又は5に記載の宿主細胞が培養され、その細胞から及び/ 又は培 養上清からタンパク質を得ることからなる請求項6〜8のいずれかに記載のタン パク質を生産する方法。 11.2種のモノマーが宿主細胞中で共発現されることからなる請求項9に記載 のヘテロダイマータンパク質を生産する方法。 12.2種のモノマーの封入体を結合させて復元することからなる請求項9に記 載のヘテロダイマータンパク質を生産する方法。 13.請求項6〜9のいずれかに記載のタンパク質のうちの少なくとも1種を有 効成分として含み、所望により、さらに通常の製剤学的担体又は補助剤、希釈剤 又は充填剤を含む医薬組成物。 14.骨、軟骨、結合組織、皮膚、粘膜、内皮、上皮、神経、脳、腎臓又は歯の 障害を治療又は予防するため、歯科インプラントへ適用するため、創傷治癒又は 組織再生過程において、肝臓組織の増殖を誘導するため、前駆細胞又は骨髄細胞 の増殖を誘導するための形態形成因子として使用するため、分化状態を保持する ため、生殖能の障害を治療するため、又は避妊のため、又は代謝に関連する疾患 を治療するための請求項13に記載の医薬組成物。 15.請求項1に記載のDNA分子の一部に相補的なアンチセンスRNA。 16.請求項1に記載のDNA分子を転写した後に得られるRNA分子を特異的 に切断するリボザイム。 17.請求項6及び7のいずれかに記載のタンパク質の発現をブロックするため の、請求項15に記載のアンチセンスRNA又は請求項16に記載のリボザイム の使用。 18.in vitro又はin vivo での患者の細胞のトランスフェクションのための請 求項1又は2に記載のDNA配列又は請求項3に記載のベクターの使用。 19.請求項6〜9のいずれかに記載のタンパク質と結合する抗体又は抗体の断 片。 20.請求項6及び7のいずれかに記載のタンパク質が特異的に結合するレセプ ター。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4423190 | 1994-07-01 | ||
DE4423190.3 | 1994-07-01 | ||
DE19511243A DE19511243A1 (de) | 1994-07-01 | 1995-03-27 | Neuer Wachstums-/Differenzierungsfaktor der TGF-beta-Familie |
DE19511243.1 | 1995-03-27 | ||
PCT/EP1995/002552 WO1996001316A1 (de) | 1994-07-01 | 1995-06-30 | NEUER WACHSTUMS-/DIFFERENZIERUNGSFAKTOR DER TGF-β-FAMILIE |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10502527A true JPH10502527A (ja) | 1998-03-10 |
JP3859703B2 JP3859703B2 (ja) | 2006-12-20 |
Family
ID=25937933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50354696A Expired - Fee Related JP3859703B2 (ja) | 1994-07-01 | 1995-06-30 | TGF−βファミリーの新規な成長/分化因子 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP3859703B2 (ja) |
CN (1) | CN1110558C (ja) |
AU (1) | AU2979895A (ja) |
DE (1) | DE19580745D2 (ja) |
IL (1) | IL114397A0 (ja) |
WO (1) | WO1996001316A1 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19525416A1 (de) | 1995-07-12 | 1997-01-16 | Bioph Biotech Entw Pharm Gmbh | Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems |
US5807713A (en) * | 1992-02-12 | 1998-09-15 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | DNA encoding growth/differentiation factor |
US7025959B1 (en) | 1992-02-12 | 2006-04-11 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | MP121, a growth/differentiation factor of the TGF-β family |
US6171584B1 (en) | 1992-02-12 | 2001-01-09 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Method of treatment with growth/differentiation factors of the TGF-β family |
EP1074620A1 (en) * | 1999-08-06 | 2001-02-07 | HyGene AG | Monomeric protein of the TGF-beta family |
US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
EP0985149A1 (en) | 1997-05-30 | 2000-03-15 | Creative Biomolecules, Inc. | Methods for evaluating tissue morphogenesis and activity |
US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
JP4950659B2 (ja) | 2003-06-27 | 2012-06-13 | エチコン、インコーポレイテッド | 胎盤組織から由来最多分娩後細胞、及びそれらを作成し使用する方法。 |
ES2350939T3 (es) | 2004-03-10 | 2011-01-28 | Scil Technology Gmbh | Implantes recubiertos, su fabricación y uso de los mismos. |
US7575751B2 (en) | 2004-04-27 | 2009-08-18 | Research Development Foundation | Activin-A mutants |
CA2567405A1 (en) | 2004-05-25 | 2005-12-08 | Stryker Corporation | Use of morphogenic proteins for treating cartilage defects |
JP5425399B2 (ja) | 2004-12-23 | 2014-02-26 | エシコン・インコーポレイテッド | 産褥由来細胞を用いたパーキンソン病および関連の障害の治療 |
DK1973559T3 (da) * | 2005-11-23 | 2013-03-25 | Acceleron Pharma Inc | Activin-ActRIIa antagonister samt anvendelser til fremme af knoglevækst |
AU2006325710B2 (en) | 2005-12-16 | 2012-05-17 | Ethicon, Inc. | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
US20090298761A1 (en) | 2006-05-17 | 2009-12-03 | Donald Engelman | Methods of treating cartilage defects using a soluble morphogenic protein complex |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
JP5452230B2 (ja) | 2006-12-21 | 2014-03-26 | ストライカー コーポレイション | 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物 |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
EP2187932B1 (en) | 2007-08-07 | 2015-01-28 | DePuy Synthes Products, LLC | Protein formulations comprising gdf-5 in aqueous acidic solution |
AU2009214629A1 (en) | 2008-02-13 | 2009-08-20 | Eric T. Choi | BMP-7 for use in treating vascular sclerosis |
CA2720845A1 (en) | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered gdf-5 formulations |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
CN107028983A (zh) | 2008-12-19 | 2017-08-11 | 德普伊新特斯产品有限责任公司 | 肺部疾病和病症的治疗 |
AU2010213575B2 (en) | 2009-02-12 | 2013-11-14 | Stryker Corporation | Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease |
US20100204124A1 (en) | 2009-02-12 | 2010-08-12 | Mary Elizabeth Pecquet Goad | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members |
WO2010110974A1 (en) | 2009-03-24 | 2010-09-30 | Stryker Corporation | Methods and compositions for tissue engineering |
CA2756600C (en) | 2009-03-26 | 2019-08-20 | Advanced Technologies And Regenerative Medicine, Llc | Human umbilical cord tissue cells as therapy for alzheimer's disease |
WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
US20110224138A1 (en) | 2009-09-09 | 2011-09-15 | Julie Krop | Methods for treating pain induced by injuries and diseases of an articular joint |
EP2352750B1 (en) | 2009-09-17 | 2012-06-13 | Stryker Corporation | Buffers for controlling the ph of bone morphogenetic proteins |
EP2516456A1 (en) | 2009-12-22 | 2012-10-31 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
ES2676556T3 (es) | 2011-12-23 | 2018-07-20 | Depuy Synthes Products Llc | Detección de células derivadas de tejido del cordón umbilical humano |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ217727A (en) * | 1985-10-03 | 1990-05-28 | Genentech Inc | Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it |
WO1993016099A2 (en) * | 1992-02-12 | 1993-08-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Dna sequences encoding novel growth/differentiation factors |
-
1995
- 1995-06-29 IL IL11439795D patent/IL114397A0/xx unknown
- 1995-06-30 AU AU29798/95A patent/AU2979895A/en not_active Abandoned
- 1995-06-30 DE DE19580745T patent/DE19580745D2/de not_active Ceased
- 1995-06-30 WO PCT/EP1995/002552 patent/WO1996001316A1/de active Application Filing
- 1995-06-30 CN CN95193816A patent/CN1110558C/zh not_active Expired - Fee Related
- 1995-06-30 JP JP50354696A patent/JP3859703B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1996001316A1 (de) | 1996-01-18 |
JP3859703B2 (ja) | 2006-12-20 |
DE19580745D2 (de) | 1999-03-11 |
IL114397A0 (en) | 1995-10-31 |
AU2979895A (en) | 1996-01-25 |
CN1110558C (zh) | 2003-06-04 |
CN1151758A (zh) | 1997-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10502527A (ja) | TGF−βファミリーの新規な成長/分化因子 | |
JP3795068B2 (ja) | Mp52蛋白質 | |
US7425334B2 (en) | Methods of making antibodies that bind Nogo | |
JP2761513B2 (ja) | 組換え繊維芽細胞成長因子 | |
DE69531892T2 (de) | Fibroblasten-wachstumsfaktor 10 | |
CZ287810B6 (cs) | Sekvence DNA, rekombinantní molekula DNA s jejím obsahem, způsob výroby proteinu ze skupiny látek TGF-beta, farmaceutický prostředek s jeho obsahem, protilátka nebo její fragment a její použití | |
CA2170405A1 (en) | Activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family | |
US5731167A (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy | |
EP1114156B1 (en) | Mammalian transforming growth factor beta - 9 (ztgfss9) | |
JP2002511762A (ja) | ネズミおよびヒトのサーベラス様蛋白およびそれらを含有する組成物 | |
WO2000009657A2 (en) | Methods of modulating of angiogenesis | |
KR20070036057A (ko) | 코브라 베놈 인자-유사 기능을 갖는 사람 보체 c3 유도체 | |
PT98695A (pt) | Gene codificador do factor neurotrofico de ligacao a heparina | |
US5408041A (en) | Process of purifying antler-derived bone growth factors | |
US7129054B2 (en) | Antibodies to a growth/differentiation factor of the TGF-β family | |
JP3903503B2 (ja) | 可溶性ポリペプチド | |
US6171584B1 (en) | Method of treatment with growth/differentiation factors of the TGF-β family | |
JP2000517187A (ja) | 繊維芽細胞増殖因子相同因子(fhf)及び使用方法 | |
US20020197666A1 (en) | Human chordin-related proteins and polynucleotides encoding them | |
JP2002526418A (ja) | 血管形成を阻害するための組成物と方法 | |
US5807713A (en) | DNA encoding growth/differentiation factor | |
Tavakkol | Molecular cloning of porcine α1-microglobulin/HI-30 reveals developmental and tissue-specific expression of two variant messenger ribonucleic acids | |
US7939635B2 (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy | |
CA2079291A1 (en) | Activities of heparin binding neurite-outgrowth promoting factor | |
US20020127594A1 (en) | Don-1 gene and polypeptides and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060829 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060920 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100929 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |